Abstract 298P
Background
Adenoid cystic carcinoma (ACC) of the breast is a rare subtype of breast cancer that is characterized by more favorable outcomes than extramammary ACC. Its rarity makes the establishment of standardized treatment protocols challenging. This study aimed to develop a machine learning (ML)-based prognostic model that improves the accuracy of survival rate predictions for patients with ACC.
Methods
The SEER database provided the data used for this study’s analysis (2000–2020). Patients who met any of the following criteria were excluded: diagnosis not confirmed by histology, previous history of cancer or other concurrent malignancies, or unknown data. To identify prognostic variables, we conducted Cox regression and constructed prognostic models using five ML algorithms to predict the 5-year survival. Patient records were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
The study population comprised 1212 patients. The median patient age was 60 years, and the median tumor size was 1.9 cm. The largest racial group was white (79.5 %). Furthermore, most cases were localized (95.1%), T1 (56.2%), and N0(96.4%). The most common type of surgery performed was partial mastectomy (74.8%). Analysis of the therapeutic options revealed significantly different survival rates. While surgery + RT had a 94.9% overall 5-year survival rate, surgery alone had a rate of 91%. For surgery + CTX, the survival rate was 83.5% and 80.1% for surgery + CTX + RT. The corresponding cancer specific survival rates were 68.5%, 63.5%, 75%, and 70.8%, respectively. The ML models demonstrated strong predictive capabilities, with random forest classifier performing the best. ML identified that the most contributing factors were age, followed by the N component of the AJCC stage and ER status.
Conclusions
ML approaches provide superior predictive performance compared with traditional statistical methods. The developed models can significantly aid personalized treatment planning and improve the clinical outcomes of patients with ACC.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
269P - Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
Presenter: Benedetta Pellegrino
Session: Poster session 14
270P - Dissecting molecular heterogeneity of luminal breast cancers using an ion mobility DIA proteomic approach
Presenter: Anne Patsouris
Session: Poster session 14
271P - Overall expression of human endogenous retroviruses in early breast cancer and their correlation with immunogenicity
Presenter: Julie Lecuelle
Session: Poster session 14
272P - Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC
Presenter: Francesca Ligorio
Session: Poster session 14
274P - A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3
Presenter: Giorgi Dzagnidze
Session: Poster session 14
275P - Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer
Presenter: Ting Luo
Session: Poster session 14
276P - SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07
Presenter: Cai Liu
Session: Poster session 14
277P - Long term follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of trastuzumab in patients with HER2-positive breast cancer
Presenter: Jinmei Zhou
Session: Poster session 14
Resources:
Abstract
278P - Prognostic and biologic significance of HER2-low early-stage breast cancer with long-term follow-up
Presenter: Yuka Niwa
Session: Poster session 14
280P - Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making
Presenter: Marta Tapia Céspedes
Session: Poster session 14